Ferring Pharmaceuticals acquires global rights to MILPROSA (progesterone vaginal ring)

Ferring Pharmaceuticals acquires global rights to MILPROSA (progesterone vaginal ring)
28 September 2015 pulse

Ferring Pharmaceuticals acquires global rights to MILPROSA (progesterone vaginal ring)

Saint-Prex, Switzerland – September 28, 2015 –

Ferring Pharmaceuticals announced today that it has acquired the global rights to MILPROSATM (progesterone vaginal ring) from Teva Women’s Health, Inc. MILPROSA has the potential to be the first once-weekly progesterone treatment for luteal phase support in women undergoing Assisted Reproductive Technology (ART) treatment if approved by regulatory authorities in the United States.

MILPROSA is a soft, flexible silicone-based vaginal ring designed to deliver a daily 11 mg dose of progesterone over the course of one week.1

“Ferring is a leader in infertility and MILPROSA, if approved, would enhance our broad treatment portfolio in this area. Equally important to Ferring is that MILPROSA would offer a weekly treatment regimen for patients and a new treatment option for doctors,” said Michel Pettigrew, President of the Ferring Executive Board and COO.

– ENDS –

About Ferring Pharmaceuticals

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

MILPROSA and FERRING are trademarks of Ferring B.V.

For more information, please contact

Nicole Barraud-Estoppey
+41 (0) 58 301 00 53
Nicole.Barraud-Estoppey@ferring.com

Helen Gallagher
+41 (0) 58 301 00 51
helen.gallagher@ferring.com

References

  1. Stadtmauer, L. et al. Fertil Steril 2013;99:1543–9

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK